-
Apr 17 |
Diagnostics World | Researchers at The University of Texas at El Paso (UTEP) are developing a point-of-care device for diagnosing colorectal cancer which, like blood glucose devices, uses electrochemical sensors. The microchip electrode features an immunosensor that detects disease biomarkers in a drop of blood, opening the possibility of an accessible, inexpensive test for the nation’s second leading cause of cancer-related deaths.
More
-
Apr 16 |
Diagnostics World | Magnetic flexible endoscopes (MFEs) have up to now had a few disadvantages limiting their use inside the human body for performing virtual biopsies, notably navigation-related difficulties related to their traditional cylindrical shape. These robot-assisted devices use magnetic forces to propel and maneuver through lumens like the colon, but rotation happens in only two directions that limits the scope's ability to effectively perform procedures.
More
-
Apr 15 |
Diagnostics World | The “bioenergetic capacity” of individuals, as marked by the level of certain cognition-associated molecules in the blood, could potentially be predictive of the risk of developing Alzheimer’s and other age-related diseases. A simulated clinical trial suggests that turning back the wheels on that biological clock could be just as effective at slowing cognitive decline as the latest drug to be approved for that purpose by the U.S. Food and Drug Administration.
More
-
Apr 10 |
Diagnostics World | Researchers worldwide are looking to revamp traditional approaches to medical imaging and develop alternative solutions that could improve visualization, speed, and accuracy in diagnostic settings. At the University of Arkansas, for example, one group is developing an AI tool designed to help radiologists and doctors analyze chest X-rays and computed tomography (CT) scans, with an emphasis on understanding how the AI assistant arrives at its conclusions.
More
-
Apr 08 |
Diagnostics World | The impact of the throat microbiome on the health of older individuals has gone unappreciated, especially among individuals being cared for in long-term care facilities. One big reason is that they are largely isolated and often forgotten by the public, even as these facilities have become home to a greater proportion of the overall population.
More
-
Apr 04 |
Diagnostics World | Atrial Fibrillation (AFib) is a fast-growing public health crisis—three times more common than once thought. Today, at least 10.55 million US adults have AFib, far exceeding the 3.3 million cases researchers predicted for the year 2020 in 1996. And this crisis is only growing.
More
-
Apr 03 |
Diagnostics World | Last week, Babson Diagnostics entered an agreement with Sam’s Club to offer BetterWay blood testing. BetterWay is currently available in seven Sam’s Club pharmacies in the greater Austin area. The agreement with Sam’s Club marks a significant milestone for accessible blood testing for patients.
More
-
Apr 01 |
Diagnostics World | The U.S. District Court for the Eastern District of Texas granted a motion for summary judgment yesterday, vacating the FDA rule that would have regulated LDTs as medical devices under the Federal Food, Drug and Cosmetic Act.
More
-
Mar 27 |
Diagnostics World | PathAI received full qualification for AIM-MASH AI Assist1; Mayo Clinic Laboratories and Amprion announced a collaboration to expand access to Amprion's SAAmplify–αSYN (CSF) test across the United States; and more.
More
-
Mar 26 |
Diagnostics World | Curevo will advance development of amezosvatein, the company’s vaccine for shingles; Garuda aims to address the growing need for off-the-shelf and cost-effective solution to stem cell transplants; and more.
More
-
Apr 18 |
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA. As an inflammatory autoimmune condition impacting the spine, axSpA often goes undiagnosed, mistaken for persistent lower back pain for 7-10 years before an accurate diagnosis. There is an urgent need to decrease the diagnostic delay for axSpA. If untreated, axSpA is a highly debilitating disease that causes irreversible spinal fusion leading to reduced mobility and quality of life. It can strike at any age, but typically begins before age 45, during the most productive years of a person’s life.
More
-
Apr 18 |
More
-
Apr 16 |
CluePoints, provider of leading statistical and AI-driven software solutions, has been named as a finalist in the ‘Innovative Clinical Trial Solutions’ category at the 2025 Citeline Awards.
More
-
Apr 16 |
VieCure is making thousands of the most commonly used NCCN Chemotherapy Order Templates available on its Halo Intelligence Platform
More
-
Apr 15 |
Oxford Nanopore Technologies announced the expansion of its Compatible Products Program. New participating companies include: 10x Genomics, Agilent Technologies, Asuragen, Day Zero Diagnostics, Hamilton Robotics, NEB, Opentrons, Pathosense, and Thermo Fisher Scientific.
More
-
Apr 11 |
Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health (MDGH), a not for profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most.
More
-
Apr 09 |
More
-
Apr 08 |
A groundbreaking study published in the journal Clinical Cancer Research validates previous findings that the PROSTOX ultra test can predict long-term side effects from radiation therapy for prostate cancer, prior to starting treatment. Led by researchers at UCLA’s Department of Radiation Oncology, the study confirms the effectiveness of PROSTOX ultra, the first test capable of predicting long-term radiation side effects based on a patient’s unique genetic profile. The findings reinforce that radiation toxicity is a biologically unique response for each patient, underscoring the potential to personalize and improve cancer treatment using genetics.
More
-
Apr 07 |
More
-
Apr 01 |
AMP announced a favorable ruling in its lawsuit against the U.S. FDA over the regulation of laboratory-developed test procedures.
More
View more articles